This invention refers to a pharmaceutical composition that comprises the synergic combination of a NSAID, such as the active ingredient: S-ketorolac of tromethamine and a GABA derivative agent, such as the active ingredient: gabapentin, which are formulated with pharmaceutically acceptable excipients in a single dosing unit to be administered by oral, parenteral, topical, transdermal means or with the use of transdermal, oral or nasal inhalation devices, which is indicated for the treatment of neuropathic and/or nociceptive pain caused by different etiologies.

This invention refers to a pharmaceutical composition that comprises the synergic combination of a NSAID, such as the active ingredient: S-ketorolac of tromethamine and a GABA derivative agent, such as the active ingredient: gabapentin, which are formulated with pharmaceutically acceptable excipients in a single dosing unit to be administered by oral, parenteral, topical, transdermal means or with the use of transdermal, oral or nasal inhalation devices, which is indicated for the treatment of neuropathic and/or nociceptive pain caused by different etiologies.

The object of the present invention is to potentiate the photodynamic effect in ALA-PDT and ALA-PDD. The present invention provides a pharmaceutical related to a combination of ALAs and a dynamin inhibitor.

The object of the present invention is to potentiate the photodynamic effect in ALA-PDT and ALA-PDD. The present invention provides a pharmaceutical related to a combination of ALAs and a dynamin inhibitor.

The present disclosure relates to: a solid compound formed by curcumin and arginine, which includes molar ratios between 5:1 and 1:5, with improved bioavailability properties, and which contains a solid compound comprising curcumin and arginine; the use thereof in complaints of inflammation, pain, stiffness and reduced range of movement, and in complaints that cause disability owing to the presentation of symptoms of pain, inflammation and stiffness and reduced range of movement, among others; and a pharmaceutical composition containing curcumin and L-arginine with a synergic effect in the therapeutic activity of the combination of curcumin and L-arginine, wherein the selected ratio allows a synergic effect in the therapeutic activity thereof to be obtained, and wherein an exemplary preferred ratio of curcumin to L-arginine is between 5:1 to 1:5.

The present disclosure relates to: a solid compound formed by curcumin and arginine, which includes molar ratios between 5:1 and 1:5, with improved bioavailability properties, and which contains a solid compound comprising curcumin and arginine; the use thereof in complaints of inflammation, pain, stiffness and reduced range of movement, and in complaints that cause disability owing to the presentation of symptoms of pain, inflammation and stiffness and reduced range of movement, among others; and a pharmaceutical composition containing curcumin and L-arginine with a synergic effect in the therapeutic activity of the combination of curcumin and L-arginine, wherein the selected ratio allows a synergic effect in the therapeutic activity thereof to be obtained, and wherein an exemplary preferred ratio of curcumin to L-arginine is between 5:1 to 1:5.

Various embodiments of the invention relate to compositions comprising vitamins, minerals and trace elements, antioxidants, amino acids, probiotics, and other components and methods for using such compositions to treat or prevent diseases associated with oxidative stress, including cardiovascular disease.

Various embodiments of the invention relate to compositions comprising vitamins, minerals and trace elements, antioxidants, amino acids, probiotics, and other components and methods for using such compositions to treat or prevent diseases associated with oxidative stress, including cardiovascular disease.

Various embodiments of the invention relate to compositions comprising vitamins, minerals and trace elements, antioxidants, amino acids, probiotics, and other components and methods for using such compositions to treat or prevent diseases associated with oxidative stress, including cardiovascular disease.

A pharmaceutical composition for treating skin infections is described herein. A method using a pharmaceutical composition for treating skin infections is described herein. A pharmaceutical composition for treating skin infections may comprise, in 100 parts of the composition, 1-99 parts of a pharmaceutically acceptable excipient; 99-1 parts of a keratolytic; 99-1 parts ethyl pyruvate; and 99-1 parts povidone iodine. A method for treating skin infections may comprise topical application of a composition to an infected skin cell for a treatment period.